A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT ID: NCT00505778

Last Updated: 2013-04-22

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1027 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, in the US, Asacol therapy is indicated in divided doses for the maintenance of remission of ulcerative colitis at 1.6 g/day. A once daily dose is potentially beneficial to patients and physicians alike. This study will answer the following questions about once daily dosing: (1) does efficacy differ between once daily and twice daily dosing, (2) do patients prefer a once daily dosing regimen, and (3) is compliance better? This study will confirm whether there are benefits to once daily dosing beyond increased convenience. In order to understand how the QD regimen compares to BID in a "real life" practice setting, the patient will remain on the total daily dose of Asacol (1.6 g/day to 2.4 g/day) on which they were maintained in remission, but will be assigned to either a QD or BID regimen. This is an investigator-blinded study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mesalamine (Asacol) Once-Daily

an oral, once daily (QD) mesalamine regimen (1.6 - 2.4 g/day)

Group Type ACTIVE_COMPARATOR

Mesalamine Once-Daily

Intervention Type DRUG

Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks

Mesalamine (Asacol) Twice-Daily

an oral, twice daily (BID) mesalamine regimen (1.6 - 2.4 g/day)

Group Type ACTIVE_COMPARATOR

Mesalamine Twice-Daily

Intervention Type DRUG

Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mesalamine Once-Daily

Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks

Intervention Type DRUG

Mesalamine Twice-Daily

Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Asacol QD Asacol BID

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented history of ulcerative colitis that has been successfully maintained in remission for at least 3 months prior to study entry
* At least one flare in the past 18 months
* Utilizing a stable maintenance dose of oral Asacol of 1.6 g/day up to 2.4 g/day (stable dose is defined as the same dose for the past 3 months)
* Females must be postmenopausal or surgically sterile or have a negative urine pregnancy test and practice acceptable contraception

Exclusion Criteria

* History of or current renal disease
* History of hepatic disease
* History of allergy or hypersensitivity to salicylates, aminosalicylates
* Treatment with immunomodulatory therapy, biologic therapy or corticosteroids within 90 days of screening
* Received any antidiarrheals, antispasmodics, or antibiotic within 1 month of screening
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Warner Chilcott

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tom G Todaro, MD

Role: STUDY_DIRECTOR

Procter and Gamble

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Facility

Athens, Alabama, United States

Site Status

Research Facility

Birmingham, Alabama, United States

Site Status

Research Facility

Birmingham, Alabama, United States

Site Status

Research Facility

Dothan, Alabama, United States

Site Status

Research Facility

Phoenix, Arizona, United States

Site Status

Research Facility

Scottsdale, Arizona, United States

Site Status

Research Facility

Tucson, Arizona, United States

Site Status

Research Facility

Tuscon, Arizona, United States

Site Status

Research Facility

Little Rock, Arkansas, United States

Site Status

Research Facility

Lowell, Arkansas, United States

Site Status

Research Facility

Anaheim, California, United States

Site Status

Research Facility

Beverly Hills, California, United States

Site Status

Research Facility

Chico, California, United States

Site Status

Research Facility

Encinitas, California, United States

Site Status

Research Facility

Folsom, California, United States

Site Status

Research Facility

La Mesa, California, United States

Site Status

Research Facility

Lancaster, California, United States

Site Status

Research Facility

Long Beach, California, United States

Site Status

Research Facility

Los Angeles, California, United States

Site Status

Research Facility

Los Angeles, California, United States

Site Status

Research Facility

Madera, California, United States

Site Status

Research Facility

Merced, California, United States

Site Status

Research Facility

Mission Hills, California, United States

Site Status

Research Facility

Monterey, California, United States

Site Status

Research Facility

Murrieta, California, United States

Site Status

Research Facility

Oakland, California, United States

Site Status

Research Facility

Orange, California, United States

Site Status

Research Facility

Palm Springs, California, United States

Site Status

Research Facility

San Carlos, California, United States

Site Status

Research Facility

San Diego, California, United States

Site Status

Research Facility

San Diego, California, United States

Site Status

Research Facility

San Diego, California, United States

Site Status

Research Facility

San Francisco, California, United States

Site Status

Research Facility

San Francisco, California, United States

Site Status

Research Facility

Torrance, California, United States

Site Status

Research Facility

Torrance, California, United States

Site Status

Research Facility

Upland, California, United States

Site Status

Research Facility

Englewood, Colorado, United States

Site Status

Research Facility

Golden, Colorado, United States

Site Status

Research Facility

Lafayette, Colorado, United States

Site Status

Research Facility

Pueblo, Colorado, United States

Site Status

Research Facility

Hartford, Connecticut, United States

Site Status

Research Facility

Meriden, Connecticut, United States

Site Status

Research Facility

New Haven, Connecticut, United States

Site Status

Research Facility

Norwalk, Connecticut, United States

Site Status

Research Facility

Torrington, Connecticut, United States

Site Status

Research Facility

Washington D.C., District of Columbia, United States

Site Status

Research Facility

Aventura, Florida, United States

Site Status

Research Facility

Fort Lauderdale, Florida, United States

Site Status

Research Facility

Gainesville, Florida, United States

Site Status

Research Facility

Hollywood, Florida, United States

Site Status

Research Facility

Jacksonville, Florida, United States

Site Status

Research Facility

Jacksonville, Florida, United States

Site Status

Research Facility

Largo, Florida, United States

Site Status

Research Facility

Maitland, Florida, United States

Site Status

Research Facility

Naples, Florida, United States

Site Status

Research Facility

New Port Richey, Florida, United States

Site Status

Research Facility

North Miami Beach, Florida, United States

Site Status

Research Facility

Orlando, Florida, United States

Site Status

Research Facility

Palm Harbor, Florida, United States

Site Status

Research Facility

Port Orange, Florida, United States

Site Status

Research Facility

St. Petersburg, Florida, United States

Site Status

Research Facility

St. Petersburg, Florida, United States

Site Status

Research Facility

Tallahassee, Florida, United States

Site Status

Research Facility

Tampa, Florida, United States

Site Status

Research Facility

Tampa, Florida, United States

Site Status

Research Facility

Trinity, Florida, United States

Site Status

Research Facility

Winter Park, Florida, United States

Site Status

Research Facility

Zephyrhills, Florida, United States

Site Status

Research Facility

Atlanta, Georgia, United States

Site Status

Research Facility

Columbus, Georgia, United States

Site Status

Research Facility

Decatur, Georgia, United States

Site Status

Research Facility

Marietta, Georgia, United States

Site Status

Research Facility

Marietta, Georgia, United States

Site Status

Research Facility

Newnan, Georgia, United States

Site Status

Research Facility

Savannah, Georgia, United States

Site Status

Research Facility

Boise, Idaho, United States

Site Status

Research Facility

Idaho Falls, Idaho, United States

Site Status

Research Facility

Arlington Heights, Illinois, United States

Site Status

Research Facility

Berwyn, Illinois, United States

Site Status

Research Facility

Chicago, Illinois, United States

Site Status

Research Facility

Elgin, Illinois, United States

Site Status

Research Facility

Highland Park, Illinois, United States

Site Status

Research Facility

Hoffman Estates, Illinois, United States

Site Status

Research Facility

Homewood, Illinois, United States

Site Status

Research Facility

Lake Barrington, Illinois, United States

Site Status

Research Facility

Oak Lawn, Illinois, United States

Site Status

Research Facility

Peoria, Illinois, United States

Site Status

Research Facility

Urbana, Illinois, United States

Site Status

Research Facility

Anderson, Indiana, United States

Site Status

Research Facility

Bloomington, Indiana, United States

Site Status

Research Facility

Indianapolis, Indiana, United States

Site Status

Research Facility

Indianapolis, Indiana, United States

Site Status

Research Facility

South Bend, Indiana, United States

Site Status

Research Facility

Clive, Iowa, United States

Site Status

Research Facility

Davenport, Iowa, United States

Site Status

Research Facility

Waterloo, Iowa, United States

Site Status

Research Facility

Pratt, Kansas, United States

Site Status

Research Facility

Topeka, Kansas, United States

Site Status

Research Site

Whichita, Kansas, United States

Site Status

Research Facility

Bowling Green, Kentucky, United States

Site Status

Research Facility

Louisville, Kentucky, United States

Site Status

Research Facility

Louisville, Kentucky, United States

Site Status

Research Facility

Alexandria, Louisiana, United States

Site Status

Research Facility

Lafayette, Louisiana, United States

Site Status

Research Facility

Metairie, Louisiana, United States

Site Status

Research Facility

Monroe, Louisiana, United States

Site Status

Research Facility

Shreveport, Louisiana, United States

Site Status

Research Facility

Bangor, Maine, United States

Site Status

Research Facility

Chevy Chase, Maryland, United States

Site Status

Research Facility

College Park, Maryland, United States

Site Status

Research Facility

Greenbelt, Maryland, United States

Site Status

Research Facility

Hagerstown, Maryland, United States

Site Status

Research Facility

Hollywood, Maryland, United States

Site Status

Research Facility

Lutherville, Maryland, United States

Site Status

Research Facility

Reisterstown, Maryland, United States

Site Status

Research Facility

Rockville, Maryland, United States

Site Status

Research Facility

Rockville, Maryland, United States

Site Status

Research Facility

Boston, Massachusetts, United States

Site Status

Research Facility

Boston, Massachusetts, United States

Site Status

Research Facility

Braintree, Massachusetts, United States

Site Status

Research Facility

Southbridge, Massachusetts, United States

Site Status

Research Facility

Chesterfield, Michigan, United States

Site Status

Research Facility

Detroit, Michigan, United States

Site Status

Research Facility

Kalamazoo, Michigan, United States

Site Status

Research Facility

Troy, Michigan, United States

Site Status

Research Facility

West Bloomfied, Michigan, United States

Site Status

Research Facility

Wyoming, Michigan, United States

Site Status

Research Facility

Rochester, Minnesota, United States

Site Status

Research Facility

Tupelo, Mississippi, United States

Site Status

Research Facility

Cape Girardeau, Missouri, United States

Site Status

Research Facility

Columbia, Missouri, United States

Site Status

Research Facility

Jefferson City, Missouri, United States

Site Status

Research Facility

Mexico, Missouri, United States

Site Status

Research Facility

St Louis, Missouri, United States

Site Status

Research Facility

Las Vegas, Nevada, United States

Site Status

Research Facility

Somersworth, New Hampshire, United States

Site Status

Research Facility

Camden, New Jersey, United States

Site Status

Research Facility

Cedar Knolls, New Jersey, United States

Site Status

Research Facility

Egg Harbor, New Jersey, United States

Site Status

Research Site

Hackensack, New Jersey, United States

Site Status

Research Facility

Ocean City, New Jersey, United States

Site Status

Research Facility

South Plainfield, New Jersey, United States

Site Status

Research Facility

Albuquerque, New Mexico, United States

Site Status

Research Facility

Babylon, New York, United States

Site Status

Research Facility

Binghamton, New York, United States

Site Status

Research Facility

Brooklyn, New York, United States

Site Status

Research Facility

Brooklyn, New York, United States

Site Status

Research Facility

Cheektowaga, New York, United States

Site Status

Research Facility

Cortland, New York, United States

Site Status

Research Facility

Forest Hills, New York, United States

Site Status

Research Facility

Garden City, New York, United States

Site Status

Research Facility

Great Neck, New York, United States

Site Status

Research Facility

Great Neck, New York, United States

Site Status

Research Facility

Lake Success, New York, United States

Site Status

Research Facility

New York, New York, United States

Site Status

Research Facility

New York, New York, United States

Site Status

Research Facility

Pittsford, New York, United States

Site Status

Research Facility

Port Jefferson Station, New York, United States

Site Status

Research Facility

Rochester, New York, United States

Site Status

Research Facility

Rochester, New York, United States

Site Status

Research Facility

Boone, North Carolina, United States

Site Status

Research Facility

Charlotte, North Carolina, United States

Site Status

Research Facility

Greensboro, North Carolina, United States

Site Status

Research Facility

Greenville, North Carolina, United States

Site Status

Research Facility

Jacksonville, North Carolina, United States

Site Status

Research Facility

Kinston, North Carolina, United States

Site Status

Research Facility

Morganton, North Carolina, United States

Site Status

Research Facility

Mount Airy, North Carolina, United States

Site Status

Research Facility

New Bern, North Carolina, United States

Site Status

Research Facility

Pinehurst, North Carolina, United States

Site Status

Research Facility

Raleigh, North Carolina, United States

Site Status

Research Facility

Wilmington, North Carolina, United States

Site Status

Research Facility

Bismarck, North Dakota, United States

Site Status

Research Facility

Akron, Ohio, United States

Site Status

Research Facility

Canton, Ohio, United States

Site Status

Research Facility

Cincinnati, Ohio, United States

Site Status

Research Facility

Cincinnati, Ohio, United States

Site Status

Research Facility

Cleveland, Ohio, United States

Site Status

Research Facility

Dayton, Ohio, United States

Site Status

Research Facility

Dayton, Ohio, United States

Site Status

Research Facility

Mentor, Ohio, United States

Site Status

Research Facility

Toledo, Ohio, United States

Site Status

Research Facility

Westlake, Ohio, United States

Site Status

Research Facility

Tulsa, Oklahoma, United States

Site Status

Research Facility

Portland, Oregon, United States

Site Status

Research Facility

Allentown, Pennsylvania, United States

Site Status

Research Facility

Beaver Falls, Pennsylvania, United States

Site Status

Research Facility

Clairton, Pennsylvania, United States

Site Status

Research Facility

Indiana, Pennsylvania, United States

Site Status

Research Facility

Lancaster, Pennsylvania, United States

Site Status

Research Facility

Philadelphia, Pennsylvania, United States

Site Status

Research Facility

Phoenixville, Pennsylvania, United States

Site Status

Research Facility

Pittsburgh, Pennsylvania, United States

Site Status

Research Facility

Pittsburgh, Pennsylvania, United States

Site Status

Research Facility

Sewickley, Pennsylvania, United States

Site Status

Research Facility

Souderton, Pennsylvania, United States

Site Status

Research Facility

Uniontown, Pennsylvania, United States

Site Status

Research Facility

Warwick, Rhode Island, United States

Site Status

Research Facility

Columbia, South Carolina, United States

Site Status

Research Facility

Columbia, South Carolina, United States

Site Status

Research Facility

Greer, South Carolina, United States

Site Status

Research Facility

Jackson, Tennessee, United States

Site Status

Research Facility

Jackson, Tennessee, United States

Site Status

Research Facility

Memphis, Tennessee, United States

Site Status

Research Facility

Morristown, Tennessee, United States

Site Status

Research Facility

Amarillo, Texas, United States

Site Status

Research Facility

Fort Worth, Texas, United States

Site Status

Research Facility

Greenville, Texas, United States

Site Status

Research Facility

Houston, Texas, United States

Site Status

Research Facility

Houston, Texas, United States

Site Status

Research Facility

Houston, Texas, United States

Site Status

Research Facility

Lewisville, Texas, United States

Site Status

Research Facility

Longview, Texas, United States

Site Status

Research Facility

Odessa, Texas, United States

Site Status

Research Facility

Pasadena, Texas, United States

Site Status

Research Facility

Plano, Texas, United States

Site Status

Research Facility

San Antonio, Texas, United States

Site Status

Research Facility

Ogden, Utah, United States

Site Status

Research Facility

Salt Lake City, Utah, United States

Site Status

Research Facility

West Valley City, Utah, United States

Site Status

Research Facility

Alexandria, Virginia, United States

Site Status

Research Facility

Chesapeake, Virginia, United States

Site Status

Research Facility

Fairfax, Virginia, United States

Site Status

Research Facility

Norfolk, Virginia, United States

Site Status

Research Facility

Virginia Beach, Virginia, United States

Site Status

Research Facility

Winchester, Virginia, United States

Site Status

Research Facility

Seattle, Washington, United States

Site Status

Research Facility

Spokane, Washington, United States

Site Status

Research Facility

Tacoma, Washington, United States

Site Status

Research Facility

Wenatchee, Washington, United States

Site Status

Research Facility

Milwaukee, Wisconsin, United States

Site Status

Research Facility

Monroe, Wisconsin, United States

Site Status

Research Facility

Abbotsford, British Columbia, Canada

Site Status

Research Facility

Guelph, Ontario, Canada

Site Status

Research Facility

Hamilton, Ontario, Canada

Site Status

Research Facility

Ottawa, Ontario, Canada

Site Status

Research Facility

Toronto, Ontario, Canada

Site Status

Research Facility

Toronto, Ontario, Canada

Site Status

Research Facility

Montreal, Quebec, Canada

Site Status

Research Facility

Montreal, Quebec, Canada

Site Status

Research Facility

Québec, Quebec, Canada

Site Status

Research Facility

Québec, Quebec, Canada

Site Status

Research Facility

Ponce, , Puerto Rico

Site Status

Research Facility

San Juan, , Puerto Rico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Puerto Rico

References

Explore related publications, articles, or registry entries linked to this study.

Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010 Apr;138(4):1286-96, 1296.e1-3. doi: 10.1053/j.gastro.2009.12.054. Epub 2010 Jan 11.

Reference Type DERIVED
PMID: 20064514 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.